CDC42 and melanoma: As shown in Figure 2b,c, in the melanoma validation cohort, patients with CDC42 gene set mutations had significantly longer PFS and OS (OS: p = 1.16E‐2, HR = 0.38, 95% CI = 0.17–0.83; PFS: p = 1.18E‐2, HR = 0.49, 95% CI = 0.28–0.86).